NASDAQ · NXL
Healthcare · Medical - Devices
$0.33
Up+$0.00 (+0.45%)
Updated Aug 23, 2026, 6:56 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NXL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NXL.
NXL research
Company profile and research snapshot.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2025 | Maxim Group | Buy | — |
| Dec 5, 2024 | Maxim Group | Hold | — |
| Oct 9, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
ChartMill · Jun 25, 2026
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Yahoo · Jun 23, 2026
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil Award-winning research evaluated Nexalin’s DIFS™ 15 mA, 77.5 Hz platform for insomnia symptoms in patients with comorbid anxiety, with the primary reported finding being a significant, durable improvement in sleep quality Independent scientific recognition further
Yahoo · Jun 16, 2026
Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported Presentations of clinical data further strengthen the scientific viability of Nexalin’s new proprietary non-invasive approach
Benzinga · Jun 16, 2026
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of lifeData to be presented include 77.8% anxiety
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NXL.
